Background: FMX101 4% topical minocycline foam has been shown to be an effective and safe treatment for acne vulgaris (AV).
Objective: To further evaluate the efficacy and safety of FMX101 4% in treating moderate to severe acne vulgaris.
Methods: A 12-week, multicenter, randomized (1:1), double-blind, vehicle-controlled study was conducted.
Cyanoacrylates (CAs) were not widely adopted for medical use until recently because of lingering concerns regarding the initial tissue toxicities of the short-chain CAs. The medium-chain CAs, primarily butyl-cyanoacrylate, have been widely used in Europe and Canada for several decades and have gone a long way in dispelling any lingering concerns about tissue toxicity. The newer, longer chain CA, octyl-2-cyanoacrylate (2-OCA), now has been approved for multiple uses in the United States and has achieved widespread acceptance by the medical and lay communities.
View Article and Find Full Text PDFBackground: Infliximab is a monoclonal antibody against tumor necrosis factor alpha currently approved by the U.S. FDA for the treatment of Crohn's disease and rheumatoid arthritis.
View Article and Find Full Text PDFObjective: To characterize the immune response and the apoptotic pathways that result in regression of imiquimod-treated basal cell carcinomas (BCCs).
Methods: The trial was conducted as an open-label, matched controlled, nonrandomized study. Twelve patients were assigned as either active-treatment patients or matched control subjects.
Background: Octyl-2-cyanoacrylate is U.S. Food and Drug Administration (FDA) approved for the closure of incisions and lacerations.
View Article and Find Full Text PDF